- Home
- FTHY vs ZNTL Comparison
FTHY vs ZNTL Comparison
Compare FTHY & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHY | ZNTL |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.7M | 468.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FTHY | ZNTL |
|---|---|---|
| Price | $13.65 | $5.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 102.3K | ★ 3.7M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.20 | $1.13 |
| 52 Week High | $14.98 | $6.95 |
Technical Indicators
Market Signals| Indicator | FTHY | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 67.04 |
| Support Level | $13.22 | $1.31 |
| Resistance Level | $14.26 | N/A |
| Average True Range (ATR) | 0.23 | 0.65 |
| MACD | 0.04 | 0.32 |
| Stochastic Oscillator | 85.17 | 62.87 |
Price Performance
Historical ComparisonAbout FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.